drugset / Trial / NCT07294261
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
Phase 2
Not yet recruiting
69 enrolled
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
Timeline
- Start
- 2025-12-23
- Primary completion
- 2028-10-30
- Completion
- 2028-12-30
Publications
- Results Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21.
- Results Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021 Nov 15;6(1):386. doi: 10.1038/s41392-021-00780-4.
- Results Molina-Arcas M, Downward J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 2024 Mar 11;42(3):338-357. doi: 10.1016/j.ccell.2024.02.012.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Catequentinib | Small molecule | 8 mg | — |
| Subject | Cetuximab | Monoclonal antibody | 500 mg/m2 | Intravenous |
| Subject | Garsorasib | Unknown | 400 mg | — |
| Subject | Garsorasib | Unknown | 600 mg | — |